Nox Health Appoints Frances Thorndike, Ph.D. to lead Medical & Scientific Affairs

Frances Thorndike Ph.D.Nox Health announced the appointment of Frances Thorndike, Ph.D., to the Nox Health team as Vice President of Medical & Scientific Affairs.

Dr. Thorndike joins Nox Health from Pear Therapeutics, where she most recently served as Vice President, Medical Affairs and Discovery and led the clinical effort for FDA authorization of Somryst, the first FDA-cleared prescription digital therapeutic for chronic insomnia. Previously, Dr. Thorndike was Co-founder and Chief Science Officer of BeHealth Solutions, a start-up focused on disseminating evidence-based digital therapeutics, and has also served as Assistant Professor Department of Psychiatry and Neurobehavioral Sciences at University of Virginia Health System.

“Frances has a demonstrated history of developing, evaluating, and disseminating evidence-based digital therapeutics in sleep care, along with the clinical and health outcomes that document their efficacy and we are thrilled to welcome her to the Nox team,” said Sigurjon (SK) Kristjansson, CEO of Nox Health. ‘We’re fortunate to have Frances’ expertise as we work to bring Somryst back to market and integrate Somryst into our existing offerings to provide an unparalleled sleep health experience to an even broader audience.”

“Given my work in the sleep care space for the past 19 years, I have known and held deep respect for SK and the Nox Health team for some time and we share the same passion for the science of sleep, as well as the importance of using sleep to address chronic health conditions,” said Frances Thorndike, Ph.D. Vice President of Medical & Scientific Affairs, Nox Health. “With Nox Health’s acquisition of Somryst, I am delighted to be able to join the Nox team and continue the important work of innovatively treating people with chronic insomnia.”

The addition of Somryst expands Nox Health’s comprehensive suite of tools and programs that address a critical and growing demand for sleep care management for populations suffering from chronic conditions. Somryst stands apart as the first and only FDA-cleared prescription digital therapeutic indicated to treat chronic insomnia. Its proven outcomes and remarkable track record in improving patients’ lives align with Nox Health’s mission.

Source: Nox Health

Be the first to comment

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.